Artiva Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and par value data)
| AS OF | ||
|---|---|---|
| MARCH 31,2025 | DECEMBER 31,2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $30,401 | $40,235 |
| Short-term investments | 135,562 | 145,193 |
| Other receivables (including related party amounts of $11 and $0, respectively) | 234 | 146 |
| Prepaid expenses and other current assets | 3,807 | 3,057 |
| Total current assets | 170,004 | 188,631 |
| Restricted cash | 461 | 258 |
| Property and equipment, net | 7,057 | 6,370 |
| Operating lease right-of-use assets | 13,482 | 13,794 |
| Financing lease right-of-use asset | 246 | 261 |
| Other long-term assets | 13 | 267 |
| Total assets | $191,263 | $209,581 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable (including related party amounts of $6 and $276, respectively) | $2,036 | $1,121 |
| Accrued expenses (including related party amounts of $82 and $713, respectively) | 6,375 | 7,392 |
| Current portion of operating lease liabilities | 3,594 | 3,618 |
| Current portion of financing lease liability | 126 | 122 |
| Other current liabilities | 73 | — |
| Total current liabilities | 12,204 | 12,253 |
| Operating lease liabilities, net of current portion | 10,265 | 10,570 |
| Financing lease liability, net of current portion | 11 | 44 |
| Other non-current liabilities | — | 73 |
| Total liabilities | 22,480 | 22,940 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2025, and December 31, 2024; zero shares issued and outstanding as of March 31, 2025, and December 31, 2024 | — | — |
| Common stock, $0.0001 par value; 700,000,000 shares authorized at March 31, 2025, and December 31, 2024; 24,363,119 and 24,291,607 shares issued and outstanding at March 31, 2025, and December 31, 2024, respectively | 3 | 3 |
| Additional paid-in capital | 435,775 | 433,451 |
| Accumulated other comprehensive loss | — | (129) |
| Accumulated deficit | (266,995) | (246,684) |
| Total stockholders’ equity | 168,783 | 186,641 |
| Total liabilities and stockholders’ equity | $191,263 | $209,581 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.